by In2Pharma | Oct 13, 2025 | News
The Netherlands Requests for the withdrawal of marketing authorizations and parallel import licenses for human medicines effective 31 December 2025 — the so-called “end-of-year withdrawals” — must be received by the Medicines Evaluation Board (CBG) no later than 1...
by In2Pharma | Oct 13, 2025 | News
Luxembourg A new version (V5 – September 2025) of the document ‘Fees in relation to marketing authorizations Luxembourg’ has been published. This updated version clarifies that for applications for variation type IA/IB, no fees are required for notifications (e.g.,...
by In2Pharma | Oct 9, 2025 | News
Belgium As of September 1st, 2025, the Algemene Pharmaceutische Bond (APB – General Pharmaceutical Association in Belgium) has ceased the publication of recommended retail prices (RRP) for products that do not fall under regulated pricing schemes. This decision...
by In2Pharma | Oct 1, 2025 | News
The Netherlands On July 1st, 2025, the NPS (New Psychoactive Substances) legislative amendment came into force, adding list IA to the Opium Act. The amendment is aimed at combating New Psychoactive Substances and to take more effective actions against designer drugs...
by In2Pharma | Sep 26, 2025 | News
Europe Health claims for food supplements are strictly regulated. For supplements containing plant extracts (botanicals), most claims fall under the so-called on-hold regulation. This means that the EFSA (European Food Safety Authority) has not yet issued a final...
by In2Pharma | Sep 19, 2025 | News
The Netherlands The Medicines Evaluation Board (MEB/CBG) has published an updated version of the policy document MEB45 (National implementation of additional risk minimisation measures) – version July 2025. Key changes include: – For digital materials, such as...
